
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is already seeing success as it has secured a $18.5M revenue contract with the BARDA, and the company has plans to expand its market opportunities through regulatory and clinical milestones. Additionally, the recent FDA clearance for the DeepView System further solidifies MDAI's potential for rapid growth and recurring high-margin revenue. With a potential 110% CAGR in revenue through FY26-30 and its innovative technology poised to disrupt the large and under-penetrated Advanced Wound Care market, Spectral AI is well-positioned for success in the MedTech industry.
Bears say
Spectral AI is facing potential downside to its estimates due to slow clinical and regulatory development timelines resulting in lower revenue from the BARDA PBS contract. Additionally, there is a risk of setbacks in regulatory and commercial approvals, which could require further analysis, filings, or additional clinical data. Furthermore, if there is lower uptake of the DeepView system in a commercial setting, it could also impact the company's revenue. On the upside, faster clinical and regulatory developments could lead to higher BARDA-related revenue, as well as more rapid development and commercial approval for the DeepView and DeepView M systems. Expansion into new indications and opportunities could also increase revenue, as could securing non-dilutive financing sources for international commercial opportunities or government contracts. If commercial sales are achieved in the UK or Australia, it would also be a positive for the company's revenue. However, this outlook remains negative overall due to the potential for longer timelines and lower uptake, which could impact Spectral AI's financials.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares